Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer

Tetsuya Shindo; Takeshi Niinuma; Naotaka Nishiyama; Nobuo Shinkai; Hiroshi Kitajima; Masahiro Kai; Reo Maruyama; Takashi Tokino; Naoya Masumori; Hiromu Suzuki

doi:10.18632/oncotarget.25326

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer

Tetsuya Shindo, Takeshi Niinuma, Naotaka Nishiyama, Nobuo Shinkai, Hiroshi Kitajima, Masahiro Kai, Reo Maruyama, Takashi Tokino, Naoya Masumori and Hiromu Suzuki _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:24457-24469. https://doi.org/10.18632/oncotarget.25326

Metrics: PDF 1702 views | HTML 2442 views | ?

Abstract

Tetsuya Shindo1,2, Takeshi Niinuma2, Naotaka Nishiyama1, Nobuo Shinkai1, Hiroshi Kitajima2, Masahiro Kai2, Reo Maruyama3, Takashi Tokino4, Naoya Masumori1 and Hiromu Suzuki2

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan

2Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan

3Project for Cancer Epigenome, The Cancer Institute, Japanese Foundation for Cancer, Koto-ku, Tokyo 135-8550, Japan

4Medical Genome Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan

Correspondence to:

Hiromu Suzuki, email: [email protected]

Keywords: bladder cancer; cisplatin resistance; miRNA; DNA methylation; histone modification

Abbreviations: BCa: bladder cancer; NMIBC: non-muscle invasive bladder cancer; MIBC: muscle invasive bladder cancer; CDDP: cisplatin

Received: November 07, 2017 Accepted: April 17, 2018 Published: May 11, 2018

ABSTRACT

In this study, we identified microRNAs (miRNAs) involved in cisplatin (CDDP) resistance in bladder cancer (BCa). After establishing CDDP-resistant BCa cell lines (T24RC and EJ138RC), TaqMan arrays revealed that members of the miR-200 family (miR-200b, miR-200a and miR-429) were downregulated in T24RC as compared to parental T24 cells. miR-200b was associated with CDDP sensitivity in BCa cells, and its downregulation was associated with CpG island hypermethylation. Pharmacological demethylation using 5-aza-2’-deoxycytidine restored miR-200b expression, and the combination of 5-aza-2’-deoxycytidine + CDDP strongly inhibited T24RC cell proliferation. Microarray analysis revealed that miR-200b + CDDP induced genes involved in CDDP sensitivity or cytotoxicity, including IGFBP3, ICAM1 and TNFSF10, in the resistant cells. Expression and DNA methylation of miR-200b were inversely associated in primary BCa, and low expression/high methylation was associated with poor overall survival. These results suggest downregulation of miR-200b is associated with CDDP resistance in BCa. Epigenetic silencing of miR-200b may be a marker of CDDP resistance and a useful therapeutic target for overcoming CDDP resistance in BCa.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25326

Publication Alerts

Research Papers:

Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer

Abstract